Notable Labs

Notable Labs is a platform therapeutics company focused on developing predictive precision medicines for cancer by leveraging its proprietary Predictive Precision Medicines Platform (PPMP). The company bio-simulates a cancer treatment and tries to predict the likelihood of a patient responding to that specific therapeutic.It is claimed that PPMP predicts responders with an accuracy rate of 97% and that it has been demonstrated across multiple hematological malignancies. 

The use of the platform ranges across a range of therapeutic modalities including small molecules, biologics, and cell therapies. The high-throughput automated platform has reportedly produced a large data repository in hematologic and other malignancies with 190 billion lines of data created across thousands of patient samples and therapeutic compounds.

The company had two products in the pipeline as of November 2023. These products which were at early clinical stages included Volasertib and Fosciclopirox. Volasertib is a potent Polo-like kinase 1 (PLK-1) inhibitor. PLK-1 is a key regulator of the cell cycle, is over-expressed in many cancers, and has been associated with poor survival. Fosciclopirox (CPX-POM), a pro-drug of ciclopirox, was developed by scientists at The University of Kansas Cancer Center, a National Cancer Institute designated cancer center and the Institute for Advancing Medical Innovation (IAMI), University of Kansas Medical Center’s product development enterprise. Notable and CicloMed haveperformed a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia (AML) under the terms of a co-development agreement. Phase 1B/2A trial was underway as of November 2023 at The University of Kansas Cancer Center, and Notable is applying its PPMP to assess patient response to fosciclopirox.

Key customers and partnerships

For the purpose of Phase 1B/2A clinical trial of fosciclopirox the company partnered with pharmaceutical company CicloMed. Under the agreement terms, CicloMed was expected to perform the clinical trials while Notable focuses on improving its own predictive precision medicine platform. Both companies were  paying for the ongoing clinical trial.

Funding and financials

The company’s latest funding was from a Series B round in July 2022 of which the amount was undisclosed.